Clinical Trial Update: A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated how hepatic insufficiency affects the pharmacokinetics of doravirine (MK-1439).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Doravirine (doravirine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 1 | Status: COMPLETED | Results posted: 2018-12-28